Clinical Report: Building the Airplane While Flying It – with Jonny Wray

Overview

In a video interview, Jonny Wray describes Nucleome Therapeutics’ use of Micro Capture-C to reconstruct three-dimensional DNA architecture and identify causal disease biology. The stated aim is to reveal overlooked drug targets and improve the chances of clinical success, while demonstrating the value of the platform as it develops.

Background

The article presents Wray’s work across electronic engineering, computational neuroscience, and drug discovery as guided by an interest in cutting-edge work that addresses consequential problems. Nucleome Therapeutics applies Micro Capture-C to study three-dimensional DNA architecture in the context of disease biology. The interview frames this approach as a way to investigate potential drug targets that may be missed by other approaches. It also describes an engineering-led philosophy of prioritizing workable solutions over complete understanding.

Data Highlights

The source article provides no numerical or trial data. It describes Micro Capture-C as a technology used by Nucleome Therapeutics to reconstruct three-dimensional DNA architecture and identify causal disease biology.

Key Findings

• Jonny Wray’s career has included electronic engineering, computational neuroscience, and drug discovery.
• Wray says his work is motivated by operating at the cutting edge and solving problems that matter.
• Nucleome Therapeutics uses Micro Capture-C to reconstruct the three-dimensional architecture of DNA.
• The company’s stated goal is to identify causal disease biology and uncover overlooked drug targets.
• The article links the platform’s purpose to improving the chances of clinical success, without reporting clinical outcome data.
• Wray describes an engineering-led approach: “Don’t worry about understanding everything. Get a solution that works and move on.”

Clinical Implications

The article describes a drug-discovery platform and its intended use in identifying disease biology and potential targets; it does not report clinical validation, patient outcomes, or treatment recommendations. Its stated emphasis is on demonstrating the platform’s value while addressing drug-discovery bottlenecks.

Conclusion

Wray’s interview presents Micro Capture-C as a tool for investigating three-dimensional DNA architecture and causal disease biology in drug discovery. The source describes the platform’s aims but provides no clinical or trial results.

Related Resources & Content

1. the analytical scientist — A Day in the Life of a Flying Laboratory Scientist
2. Eyecare Business — Come Fly With Me
3. the new optometrist — Eye Flier: Chuck Yeager
4. the pathologist — Trains, Planes, and AI Tools
5. ACMG American College of Medical Genetics and Ge
6. Human genetic evidence is associated with drug approval across therapeutic areas: an observational analysis of 26,278 target-disease pairs with temporal validation and feature ablation
7. Single-allele nanoscale mapping of regulatory variants | Nature Genetics